Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (27)

« Back to Publications

Correction: Psychiatrists effect on positive symptom severity and daily functioning during pharmacotherapy for first-episode psychosis patients (Scientific Reports, (2024), 14, 1, (22871), 10.1038/s41598-024-72678-4)

de Beer F. et al, (2026), Scientific Reports, 16

ntipsychotic plasma concentration as predictor of movement disorders and cardiometabolic side-effects: A comparison with prescription dose.

Liu Y. et al, (2026), Eur Neuropsychopharmacol, 105

Holistic prevention and management of physical health side-effects of psychotropic medication: second report of the Lancet Psychiatry Physical Health Commission.

Halstead S. et al, (2025), Lancet Psychiatry, 12, 673 - 699

Do women need a change in dose of prescription drugs with onset of menopause? Time to find out.

Sommer IEC. et al, (2025), BMC Med, 23

Hormone replacement therapy helps prevent psychotic relapse during menopause

Brand B., (2025), Tijdschrift Voor Psychiatrie, 67

Genetic variants in COMT and ESR1 genes shape treatment response to raloxifene in schizophrenia-spectrum disorders.

Brand BA. et al, (2025), Psychoneuroendocrinology, 172

ntipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognition.

Brand BA. et al, (2024), Arch Womens Ment Health, 27, 931 - 941

Psychiatrists effect on positive symptom severity and daily functioning during pharmacotherapy for first-episode psychosis patients.

de Beer F. et al, (2024), Sci Rep, 14

Correction to: Evidence‑Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.

Brand BA. et al, (2024), Curr Psychiatry Rep, 26, 550 - 551

Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder.

Brand BA. et al, (2024), Am J Psychiatry, 181, 893 - 900

The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: Divergent effects of testosterone and estrogen.

Hamers IMH. et al, (2024), Schizophr Res, 270, 273 - 280

Sex differences need to be considered when treating women with psychotropic drugs.

Sommer IE. et al, (2024), World Psychiatry, 23, 151 - 152

ddressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium.

Koops S. et al, (2024), Schizophr Bull, 50, 5 - 8

The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial.

Brand BA. et al, (2023), Schizophr Bull, 49, 1579 - 1590

Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.

Brand BA. et al, (2023), Curr Psychiatry Rep, 25, 723 - 733

Load More